Cutaneous Toxicity from Epidermal Growth Factor Receptor Inhibitors: Would a Subcutaneous Desensitization be Helpful? Case Report
| Autor: | Daniela Di Mauro, Andrea D'Alessio, Davide Resta, Carmelo Fortugno, Simonetta Villa, Luca Geroli, S. Cecchini, Antonello Quadri |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Male
0301 basic medicine Cancer Research medicine.medical_treatment Antineoplastic Agents Pharmacology Skin Diseases 03 medical and health sciences 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols Immune Tolerance medicine Humans Panitumumab Epidermal growth factor receptor Adverse effect Aged Desensitization (medicine) EGFR inhibitors Cetuximab biology business.industry Antibodies Monoclonal General Medicine Rash ErbB Receptors Treatment Outcome 030104 developmental biology Oncology Desensitization Immunologic 030220 oncology & carcinogenesis Toxicity biology.protein Female medicine.symptom Colorectal Neoplasms business medicine.drug |
| Zdroj: | Tumori Journal. 102:S65-S68 |
| ISSN: | 2038-2529 0300-8916 |
| DOI: | 10.5301/tj.5000579 |
| Popis: | Purpose Cetuximab and panitumumab are monoclonal antibody inhibitors that bind the epidermal growth factor receptor (EGFR) currently used in the treatment of metastatic colorectal cancer. The main adverse event related to EGFR inhibitors (EGFR-Is) is cutaneous toxicity, which can cause dosage reduction and interruption of treatment. State-of-the-art management of skin toxicity associated with EGFR-Is therapy involves the topical administration of corticosteroids and oral antibiotics, but is not completely effective in the management of toxicity. Subcutaneous desensitization with increasing concentrations of monoclonal antibodies can induce a tolerance to drug administration and reduce cutaneous adverse effects. To our knowledge, this is the first case in which a reduction or a disappearance of skin toxicity caused by EGFR-Is through subcutaneous desensitization has been achieved. Case Report We present cases of 2 Caucasian patients with adenocarcinoma of the colon treated with EGFR-Is who developed severe cutaneous toxicity. A 73-year-old man presented grade 4 skin toxicity of the face and grade 3 skin toxicity of the trunk during treatment with cetuximab. A 68-year-old woman developed G2 rash on the face after the first administration of cetuximab. These patients underwent subcutaneous desensitization with increasing concentrations of EGFR-Is. After this procedure, patients restarted therapy at the optimal dosage with reduction or disappearance of skin toxicity. Conclusions These cases suggest that by giving rising doses of antibody it is possible to obtain desensitization able to prevent severe cutaneous adverse events in patients treated with EGFR-Is. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|